Santiago Rico-Rios Santiago Rico-Rios

Dr. Santiago Rico-Rios Santiago Rico-Rios

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Sclerosis
Verified
Journal Article
Open access
PDF file
VAVictòria Ayala
Victòria Ayala
LFLaia Fontdevila
Laia Fontdevila
SRSantiago Rico-Rios Santiago Rico-Rios
Santiago Rico-Rios Santiago Rico-Rios
MPMónica Povedano
Mónica Povedano
PAPol Andrés-Benito
Pol Andrés-Benito
MPManuel Portero-Otin
Manuel Portero-Otin
Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the progressive degeneration of motor neurons. The gut microbiota, a community of microorganisms in the digestive tract, has recently been implicated in ALS pathogenesis through its influence on neuroinflammation and metabolic pathways. This review explores the potential role of digestive microbiota and its metabolites in ALS progression and investigates therapeutic approaches targeting gut microbiota. Methods: A comprehensive review of the current literature was conducted to assess the relationship between gut microbiota composition, microbial metabolites, and ALS progression in patients. We searched for published reports on microbiota composition, microbial metabolites, and ALS, emphasizing the complex interplay between dysbiosis, neuroinflammation, and systemic metabolism. Special emphasis was placed on studies exploring short-chain fatty acids (SCFAs), bacterial amyloids (curli-like factors), and neurotoxins such as β-methylamino-L-alanine (BMAA). The role of the liver–gut axis was evaluated as well. The potential changes in microbiota would sustain the rationale for therapeutic strategies such as probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary interventions. Results: ALS patients exhibit gut dysbiosis, characterized by reduced SCFA-producing bacteria and an increase in potentially pathogenic genera. Of note, different studies do not agree on common patterns of microbiota being linked to ALS, supporting the need for further, more extensive studies. Dysbiosis sometimes correlates with systemic inflammation and disrupted liver function, amplifying neuroinflammatory responses. Key microbial metabolites, including SCFAs, bacterial amyloids, and BMAA, may exacerbate motor neuron degeneration by promoting protein misfolding, oxidative stress, and neuroinflammation. Emerging therapeutic strategies, including probiotics and FMT, show potential in restoring microbial balance, although clinical data in ALS patients remain limited. Conclusions: The gut microbiota could modulate neuroinflammation and systemic metabolism in ALS. Microbiota-targeted therapies, such as probiotics and dietary interventions, represent promising avenues for mitigating disease progression. Further research is required to validate these interventions through large-scale, longitudinal studies and to develop personalized microbiota-based treatments tailored to individual ALS phenotypes.

31 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
VAVictòria Ayala
Victòria Ayala
LFLaia Fontdevila
Laia Fontdevila
SRSantiago Rico-Rios Santiago Rico-Rios
Santiago Rico-Rios Santiago Rico-Rios
MPMónica Povedano
Mónica Povedano
PAPol Andrés-Benito
Pol Andrés-Benito
MPManuel Portero-Otin
Manuel Portero-Otin
Background/Objectives Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the pro-gressive degeneration of motor neurons. The gut microbiota, a community of microorganisms residing in the digestive tract, has recently been implicated in ALS pathogenesis through its in-fluence on neuroinflammation and metabolic pathways. This review explores the potential role of digestive microbiota and its metabolites in ALS progression and investigates therapeutic ap-proaches targeting gut microbiota. Methods A comprehensive review of current literature was conducted to assess the relationship between gut microbiota composition, microbial metabolites, and ALS progression in patients. Special emphasis was placed on studies exploring short-chain fatty acids (SCFAs), bacterial amyloids (curli-like factors), and neurotoxins such as β-methylamino-L-alanine (BMAA). The role of the liver-gut axis was evaluated as well. The potential changes in microbiota would sustain the rationale of ther-apeutic strategies such as probiotics, prebiotics, fecal microbiota transplantation (FMT), and die-tary interventions. Results ALS patients exhibit gut dysbiosis, characterized by reduced SCFA-producing bacteria and an increase in potentially pathogenic genera. Of note, different studies do not agree on common patterns of microbiota being linked to ALS, supporting the need for further, larger studies. In some cases, dysbiosis correlates with systemic inflammation and disrupted liver function, amplifying neuroinflammatory responses. Key microbial metabolites, including SCFAs, bacterial amyloids, and BMAA, may exacerbate motor neuron degeneration by promoting protein misfolding, oxi-dative stress, and neuroinflammation. Emerging therapeutic strategies, including probiotics and FMT, show potential in restoring microbial balance, although clinical data in ALS patients remains limited. Conclusions The gut microbiota could modulate neuroinflammation and systemic metabolism in ALS. Mi-crobiota-targeted therapies, such as probiotics and dietary interventions, represent promising avenues for mitigating disease progression. Further research is required to validate these inter-ventions through large-scale, longitudinal studies, and to develop personalized microbiota-based treatments tailored to individual ALS phenotypes.